Anti-DLL3 Antibody (anti-DLL3 arm derived from AMG-757)
Anti-DLL3 Antibody (anti-DLL3 arm derived from AMG-757)
Catalog No.: AT1540
The Anti-DLL3 Antibody is derived from the anti-DLL3 arm of Tarlatamab (AMG-757), a bispecific T-cell engager (BiTE) that simultaneously targets DLL3 on tumor cells and CD3 on T cells. This monoclonal antibody is designed for precision in targeting the Delta-like ligand 3 (DLL3) protein, a promising therapeutic target in neuroendocrine tumors, including small cell lung cancer. The antibody's specificity for DLL3 makes it an invaluable tool for research focused on cancer biology and the development of targeted cancer therapies.
The Anti-DLL3 Antibody is derived from the anti-DLL3 arm of Tarlatamab (AMG-757), a bispecific T-cell engager (BiTE) that simultaneously targets DLL3 on tumor cells and CD3 on T cells. This monoclonal antibody is designed for precision in targeting the Delta-like ligand 3 (DLL3) protein, a promising therapeutic target in neuroendocrine tumors, including small cell lung cancer. The antibody's specificity for DLL3 makes it an invaluable tool for research focused on cancer biology and the development of targeted cancer therapies.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
Please check COA/MSDS for correct molecular weight.
Calculate the dilution required to prepare a stock solution.This equation is commonly abbreviated as: C1V1 = C2V2
Frequently Asked Questions
What are Biosimilar Antibodies?
Biosimilar antibodies are research-grade recombinant antibodies designed to closely resemble approved therapeutic antibodies in terms of amino acid sequence, structural characteristics, and biological activity. These antibodies are generated using recombinant expression technologies and retain the same variable regions as their corresponding reference therapeutics, thereby preserving target specificity and binding affinity. Owing to these properties, biosimilar antibodies serve as reliable and cost-effective research reagents for applications in drug discovery, pharmacological studies, and basic biomedical research.
Research-grade biosimilar antibodies have been successfully expressed and functionally validated against a wide range of widely studied targets. These antibodies can be directly utilized as positive control reagents in drug discovery programs, as well as reference tools for rapid verification of the biological functions of target proteins in biochemical and cellular assays.
